Desai Kirti 4

What Happened Kirti Desai, Chief Financial Officer of Tevogen Bio Holdings, was granted 40,000 restricted common shares on 2026-07-10. The reported acquisition price is $0.00 (i.e., the shares were awarded, not purchased). This is an equity award (not a sale) and does not represent immediate liquidity.

Key Details

• Transaction date and type: 2026-07-10 — Award/Grant of 40,000 shares (code A). Reported price: $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Plan: Award granted under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• Vesting footnote: The award vests in three equal installments upon the earlier of (a) the first, second, and third anniversaries of the grant date and (b) achieving aggregate revenue milestones of $50M, $100M, and $150M, respectively, provided Desai remains in service on each applicable vesting date (see footnote F1).
• Filing timeliness: Reported on period date 2026-07-10; filing appears timely (no late filing flag reported).

Context Restricted stock awards are common executive compensation that vest over time or upon performance milestones; they are not an immediate buy/sell signal. Because vesting here is tied to both time and company revenue milestones, the shares will only convert to free-trading shares if those conditions and continued service requirements are met.